文献速递妇科

子宫浆液性癌的条件生存估计:用于生存期咨询与照护规划的工具

Conditional estimates for uterine serous cancer: Tools for survivorship counseling and planning.
PubMed 文献 · Gynecol Oncol · 2022-05-24

基于美国国家癌症数据库2004至2014年确诊的14,575例I–IV期子宫浆液性癌患者,按分期分层估算每年5年条件生存率及标准化死亡比。诊断时与存活5年后的5年生存率总体为52%对75%,IV期由17%升至60%(P<0.0001);结论认为条件生存的演变可用于每年重新评估预后以个体化生存期咨询与照护规划。

要点

  • 诊断时与存活5年后的5年生存率总体52%对75%,IV期17%对60%(P<0.0001)。
  • 各期5年条件生存率随随访年数递增而逐年改善,标准化死亡比相应下降。
  • 存活5年后,III期死亡风险由3.92降至2.48、IV期由6.65降至2.79(P<0.0001)。

核心结论

  • 子宫浆液性癌的条件生存随随访年数演变,可支持每年重新评估预后以个体化生存期咨询和照护规划。

研究设计与样本

  • 基于美国国家癌症数据库2004至2014年确诊的I–IV期子宫浆液性癌患者的队列分析,排除分期或生存数据缺失及合并多种恶性肿瘤者,共纳入14,575例。
  • 采用按分期分层的Kaplan-Meier法每年估算5年条件生存,以标准化死亡比(SMR)估算观察死亡与预期死亡之比(按年份、年龄、种族校正),并用多因素Cox模型分析诊断时及存活5年后的预后因素与生存关系。

主要发现

  • 分期构成:I期43%、II期8%、III期29%、IV期20%。
  • 诊断时与存活5年后的5年生存率:总体52%对75%,I期77%对81%,II期57%对72%,III期40%对66%,IV期17%对60%(P<0.0001)。
  • 5年条件生存率随每年随访递增而逐步改善,SMR随随访年数增加和分期升高而下降。
  • 诊断时与存活5年后的校正死亡风险:年龄每增加5岁为1.15对1.40,医疗补助保险为1.26对1.68,III期为3.92对2.48,IV期为6.65对2.79(P<0.0001)。

关键数值与推荐

  • 5年生存率诊断时对存活5年后:总体52%对75%(P<0.0001)。
  • I期77%对81%,II期57%对72%,III期40%对66%,IV期17%对60%(P<0.0001)。
  • 校正死亡风险诊断时对存活5年后:年龄每增加5岁1.15对1.40,医疗补助保险1.26对1.68,III期3.92对2.48,IV期6.65对2.79(P<0.0001)。

临床怎么用

  • 原文结论认为条件生存的演变可用于每年重新评估预后,以个体化生存期咨询和照护规划。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Develop conditional survival and risk-assessment estimates for uterine serous carcinoma (USC) overall and stratified by stage as tools for annual survivorship counseling and care planning. METHODS: Patients in the National Cancer Data Base diagnosed between 2004 and 2014 with stage I-IV USC were eligible. Individuals missing stage or survival data or with multiple malignancies were excluded. Five-year conditional survival was estimated using the stage-stratified Kaplan-Meier method annually during follow-up. A standardized mortality ratio (SMR) estimated the proportion of observed to expected deaths in the U.S. adjusted for year, age, and race. The relationships between prognostic factors and survival were studied using multivariate Cox modeling at diagnosis and conditioned on surviving 5-years. RESULTS: There were 14,575 participants, including 43% with stage I, 8% with stage II, 29% with stage III, and 20% with stage IV USC. Five-year survival at diagnosis vs. after surviving 5-years was 52% vs. 75% overall, 77% vs. 81% for stage I, 57% vs. 72% for stage II, 40% vs. 66% for stage III, and 17% vs. 60% for stage IV USC, respectively (P < 0.0001). Incremental improvements in 5-year conditional survival and reductions in SMR tracked with annual follow-up and higher stage. The adjusted risk of death at diagnosis vs. after surviving 5-years was 1.15 vs. 1.40 per 5-year increase of age, 1.26 vs. 1.68 for Medicaid insurance, 3.92 vs. 2.48 for stage III disease, and 6.65 vs. 2.79 for stage IV disease, respectively (P < 0.0001). CONCLUSION: In USC, the evolution of conditional survival permits annual reassessments of prognosis to tailor survivorship counseling and care planning.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Nolin AC, Tian C, Hamilton CA, et al. Conditional estimates for uterine serous cancer: Tools for survivorship counseling and planning. Gynecol Oncol. 2022. PMID: 35624045. doi:10.1016/j.ygyno.2022.05.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。